Skip to main content

Advertisement

Log in

The Levels of Ki-67 Positive are Positively Associated with Lymph Node Metastasis in Invasive Ductal Breast Cancer

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Breast cancer is the most common cancer in women worldwide. In this study, we evaluate the potential risk factors for lymph node metastasis in invasive breast cancer patients with axillary dissection. 147 patients were included into this prospective study. The prognostic biomarkers including Ki-67, human epidermal growth factor receptor 2 (HER-2), hormone receptor status, p53, and lymph node involvement were determined by immunohistochemistry. The association between lymph node metastasis and these biomarkers was analyzed. Lymph node metastasis was found in 62 patients out of 147 patients. The high levels of Ki-67 positive (greater than 20 %) were positively correlated with a higher incidence of lymph node metastasis, including the numbers of lymph nodes that contain tumor cells and the lymph node metastatic rate. The high rate of positive lymphovascular invasion (LVI) is associated with lymph node metastasis. However, the levels of Ki-67 positive were not correlated with the positive rate of LVI. There was also no association between lymph node metastasis and other prognostic biomarkers, such as HER-2, estrogen receptor, progesterone receptor, and p53. In addition, apart from p53, the levels of Ki-67 positive were correlated with other prognostic biomarkers. Our data suggest that Ki-67 positivity has value as a prognostic and predictive biomarker in breast cancer and may be a valuable proliferation marker in routine diagnosis of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893–2917.

    Article  CAS  Google Scholar 

  2. Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007). Overview of resistance to systemic therapy in patients with breast cancer. Advances in Experimental Medicine and Biology, 608, 1–22.

    Article  PubMed  CAS  Google Scholar 

  3. Donegan, W. L. (1997). Tumor-related prognostic factors for breast cancer. CA: A Cancer Journal for Clinicians, 47, 28–51.

    Article  CAS  Google Scholar 

  4. Fisher, E. R., Kotwal, N., Hermann, C., & Fisher, B. (1983). Types of tumor lymphoid response and sinus histiocytosis. Relationship to five-year, disease-free survival in patients with breast cancer. Archives of Pathology and Laboratory Medicine, 107, 222–227.

    PubMed  CAS  Google Scholar 

  5. Bruno, S., & Darzynkiewicz, Z. (1992). Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Proliferation, 25, 31–40.

    Article  PubMed  CAS  Google Scholar 

  6. Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., et al. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Journal of Clinical Oncology, 20, 4292–4302.

    Article  PubMed  CAS  Google Scholar 

  7. Lipponen, P. (1999). Apoptosis in breast cancer: Relationship with other pathological parameters. Endocrine-Related Cancer, 6, 13–16.

    Article  PubMed  CAS  Google Scholar 

  8. Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2009). Thresholds for therapies: Highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of Oncology, 20, 1319–1329.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Clarke, R. B., Howell, A., Potten, C. S., & Anderson, E. (1997). Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Research, 57, 4987–4991.

    PubMed  CAS  Google Scholar 

  10. Harper-Wynne, C., Ross, G., Sacks, N., Salter, J., Nasiri, N., Iqbal, J., et al. (2002). Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiology, Biomarkers and Prevention, 11, 614–621.

    PubMed  CAS  Google Scholar 

  11. Paik, S. (2006). Molecular profiling of breast cancer. Current Opinion in Obstetrics and Gynecology, 18, 59–63.

    Article  PubMed  Google Scholar 

  12. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine, 351, 2817–2826.

    Article  PubMed  CAS  Google Scholar 

  13. de Azambuja, E., Cardoso, F., de Castro, G., Jr., Colozza, M., Mano, M. S., Durbecq, V., et al. (2007). Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. British Journal of Cancer, 96, 1504–1513.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Stuart-Harris, R., Caldas, C., Pinder, S. E., & Pharoah, P. (2008). Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast, 17, 323–334.

    Article  PubMed  CAS  Google Scholar 

  15. Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., et al. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25, 5287–5312.

    Article  PubMed  CAS  Google Scholar 

  16. de Boer, M., van Deurzen, C. H., van Dijck, J. A., Borm, G. F., van Diest, P. J., Adang, E. M., et al. (2009). Micrometastases or isolated tumor cells and the outcome of breast cancer. New England Journal of Medicine, 361, 653–663.

    Article  PubMed  Google Scholar 

  17. Cheang, M. C., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., et al. (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute, 101, 736–750.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Colozza, M., Azambuja, E., Cardoso, F., Sotiriou, C., Larsimont, D., & Piccart, M. J. (2005). Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Annals of Oncology, 16, 1723–1739.

    Article  PubMed  CAS  Google Scholar 

  19. Endl, E., & Gerdes, J. (2000). Posttranslational modifications of the KI-67 protein coincide with two major checkpoints during mitosis. Journal of Cellular Physiology, 182, 371–380.

    Article  PubMed  CAS  Google Scholar 

  20. Chae, B. J., Bae, J. S., Lee, A., Park, W. C., Seo, Y. J., Song, B. J., et al. (2009). p53 as a specific prognostic factor in triple-negative breast cancer. Japanese Journal of Clinical Oncology, 39, 217–224.

    Article  PubMed  Google Scholar 

  21. Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010). Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncology, 11, 174–183.

    Article  CAS  Google Scholar 

  22. Bozzetti, C., Musolino, A., Camisa, R., Bisagni, G., Flora, M., Bassano, C., et al. (2006). Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: The role of anthracycline dose intensity. American Journal of Clinical Oncology, 29, 171–177.

    Article  PubMed  CAS  Google Scholar 

  23. Colleoni, M., Viale, G., Zahrieh, D., Bottiglieri, L., Gelber, R. D., Veronesi, P., et al. (2008). Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy. Annals of Oncology, 19, 465–472.

    Article  PubMed  CAS  Google Scholar 

  24. Estevez, L. G., Cuevas, J. M., Anton, A., Florian, J., Lopez-Vega, J. M., Velasco, A., et al. (2003). Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study. Clinical Cancer Research, 9, 686–692.

    PubMed  CAS  Google Scholar 

  25. Faneyte, I. F., Kristel, P. M., & van de Vijver, M. J. (2004). Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Research, 24, 2931–2939.

    PubMed  CAS  Google Scholar 

  26. Petit, T., Wilt, M., Velten, M., Millon, R., Rodier, J. F., Borel, C., et al. (2004). Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. European Journal of Cancer, 40, 205–211.

    Article  PubMed  CAS  Google Scholar 

  27. Thames, H. D., Buchholz, T. A., & Smith, C. D. (1999). Frequency of first metastatic events in breast cancer: Implications for sequencing of systemic and local–regional treatment. Journal of Clinical Oncology, 17, 2649–2658.

    PubMed  CAS  Google Scholar 

  28. Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005). Proliferation marker Ki-67 in early breast cancer. Journal of Clinical Oncology, 23, 7212–7220.

    Article  PubMed  CAS  Google Scholar 

  29. Marrelli, D., Pinto, E., Neri, A., Megha, T., Gioffre, W., Cioppa, T., et al. (2006). Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer: A prospective study on 675 patients. Oncology Reports, 15, 425–429.

    PubMed  Google Scholar 

  30. Hanrahan, E. O., Valero, V., Gonzalez-Angulo, A. M., & Hortobagyi, G. N. (2006). Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a, bN0M0): A review of the literature. Journal of Clinical Oncology, 24, 2113–2122.

    Article  PubMed  Google Scholar 

  31. Colleoni, M., Rotmensz, N., Maisonneuve, P., Sonzogni, A., Pruneri, G., Casadio, C., et al. (2007). Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Annals of Oncology, 18, 1632–1640.

    Article  PubMed  CAS  Google Scholar 

  32. Mohammed, R. A., Martin, S. G., Mahmmod, A. M., Macmillan, R. D., Green, A. R., Paish, E. C., et al. (2011). Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: Findings from a large case series with long-term follow-up. Journal of Pathology, 223, 358–365.

    Article  PubMed  Google Scholar 

  33. Ejlertsen, B., Jensen, M. B., Nielsen, K. V., Balslev, E., Rasmussen, B. B., Willemoe, G. L., et al. (2010). HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. Journal of Clinical Oncology, 28, 984–990.

    Article  PubMed  CAS  Google Scholar 

  34. Rakovitch, E., Nofech-Mozes, S., Hanna, W., Narod, S., Thiruchelvam, D., Saskin, R., et al. (2012). HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. British Journal of Cancer, 106, 1160–1165.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  35. Nishimura, R., Okumura, Y., & Arima, N. (2008). Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: Time to progression and survival. Breast Cancer, 15, 57–64.

    Article  PubMed  Google Scholar 

  36. Pohl, G., Rudas, M., Taucher, S., Stranzl, T., Steger, G. G., Jakesz, R., et al. (2003). Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Research and Treatment, 78, 97–103.

    Article  PubMed  CAS  Google Scholar 

  37. Gasparini, G., Pozza, F., Meli, S., Reitano, M., Santini, G., & Bevilacqua, P. (1991). Breast cancer cell kinetics: Immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Research, 11, 2015–2021.

    PubMed  CAS  Google Scholar 

  38. Nicholson, R. I., McClelland, R. A., Finlay, P., Eaton, C. L., Gullick, W. J., Dixon, A. R., et al. (1993). Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European Journal of Cancer, 29A, 1018–1023.

    Article  PubMed  CAS  Google Scholar 

  39. Bottini, A., Berruti, A., Bersiga, A., Brizzi, M. P., Bruzzi, P., Aguggini, S., et al. (2001). Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. British Journal of Cancer, 85, 1106–1112.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  40. Moriki, T., Takahashi, T., Kataoka, H., Hiroi, M., Yamane, T., & Hara, H. (1996). Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: An immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status. Pathology International, 46, 953–961.

    Article  PubMed  CAS  Google Scholar 

  41. Kai, K., Nishimura, R., Arima, N., Miyayama, H., & Iwase, H. (2006). p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: A cohort study. International Journal of Clinical Oncology, 11, 426–433.

    Article  PubMed  CAS  Google Scholar 

  42. Yamashita, H., Toyama, T., Nishio, M., Ando, Y., Hamaguchi, M., Zhang, Z., et al. (2006). p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Research, 8, R48.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of interest

None of the authors have a conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Min Zhao.

Additional information

Yongxian Yin and Ke Zeng equally contribute to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yin, Y., Zeng, K., Wu, M. et al. The Levels of Ki-67 Positive are Positively Associated with Lymph Node Metastasis in Invasive Ductal Breast Cancer. Cell Biochem Biophys 70, 1145–1151 (2014). https://doi.org/10.1007/s12013-014-0034-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0034-1

Keywords

Navigation